AeroVironment Inc (AVAV): AVAV $$$... Took $67 today, drone maker,...

AVAV $$$... Took $67 today, drone maker, gl...

Pisd · 2019-01-03T19:22:38.9700000Z

AVAV $$$... Took $67 today, drone maker, gl...

Play Episode

4min

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Proactive - Interviews for investors

AI translation tech: Straker CEO talks IBM partnership

Straker Ltd CEO Grant Straker talked with Proactive at AIM"S Small and Midcap Conference about how the company is leveraging artificial intelligence to reshape the global language services industry. Straker explained how the business evolved from early content management systems into a leading AI-powered translation platform over the last 15 years. The company focuses on blending machine learning with human expertise to deliver high-quality, cost-effective language services. A key milestone has been the integration of its platform by IBM, which now uses Straker’s technology for all its internal translations. “They’ve gone from a multi-vendor traditional model to just us,” Straker said, highlighting how the move has streamlined IBM’s operations while reducing costs. He also discussed the company's proprietary "Terry" language model and its innovative quality estimation* system. This tool evaluates translated content for accuracy, determining whether it needs human review—improving efficiency and boosting gross margins. Straker outlined a clear investor case, emphasizing three pillars: financial strength, innovation, and global distribution. The company is targeting revenues of AUD 45 million for the year, with no debt, AUD 12 million in cash, and annual R&D investment of AUD 7 million. With operations in ten countries and strategic alignment with IBM’s AI stack, Straker positioned the company as well-placed to scale quickly through operating leverage in AI. #AI #StrakerLtd #GrantStraker #LanguageTech #TranslationAI #IBMPartnership #ArtificialIntelligence #InvestorUpdate #MachineTranslation #TechStocks #ASXStocks #TerryModel #QualityEstimation #ProactiveInvestors #SmallCapASX

Proactive - Interviews for investors

Cordiant Digital Infrastructure Management chair on capital strategy & growth focus

Cordiant Digital Infrastructure Ltd (LSE:CORD) Chairman Steven Marshall talked with Proactive's Stephen Gunnion about the company’s capital allocation strategy and growth outlook, particularly in the context of rising interest rates and macroeconomic pressures. Marshall highlighted how Cordiant Digital has strategically invested in cash-generative assets within two of Europe’s fastest-growing economies—Poland and the Czech Republic. “We can actually buy small bolt-on businesses, we can invest in organic growth, which actually is at a much lower cost than actually the buyback rates that we're getting,” Marshall said. The company has balanced yield and reinvestment, maintaining a dividend yield just under 5%, which is currently covered 1.8 times by free cash flow. Marshall explained the business has focused on acquiring quality mid-market assets with strong management teams and brand value. Looking ahead, Cordiant Digital aims to continue growing its portfolio through bolt-on acquisitions and organic investments, such as expanding distributed antenna broadband networks in Prague and Warsaw, and further developing data centre and mobile tower infrastructure in Poland. Marshall indicated the company is unlikely to pursue additional share buybacks in the short term, preferring to direct capital towards growth opportunities offering better long-term returns. Visit Proactive's YouTube channel for more interviews and insights. Don't forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #CordiantDigital #InfrastructureInvestment #DigitalGrowth #DividendStocks #EmergingMarkets #PolandInvestment #CzechRepublic #CapitalAllocation #TelecomInfrastructure #DataCenters #InvestorUpdate

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	59
Posts	7723
Boards Moderated	0
Alias Born	07/27/2012

Volume:	219
Day Range:
Bid:	117.02
Ask:	130.00
Last Trade Time:	7:17:56 AM EDT
Total Trades:	58

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AVAV Detailed Quote

Recent AVAV News

More AVAV News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent AVAV News

Go Ad-Free